Skip to main content
Premium Trial:

Request an Annual Quote

Genalyte Raises $44M in Series C Financing

NEW YORK (GenomeWeb) – San Diego-based diagnostics firm Genalyte today announced it has completed a $44M Series C financing round.

Khosla Ventures joined previous investors Redmile Group, Claremont Creek Ventures, and BioMed Ventures in the round.

Genalyte's CE-marked Maverick Detection System is intended for multiplexed, blood-based, point-of-care diagnostic testing. The firm said in a statement that it can provide results in 15 minutes. The platform is for research use only in the US.

"Our technology allows us to eliminate a number of inefficiencies from the system, such as the secondary appointment to have blood drawn, the large quantity of blood required, the long wait for results, and the game of phone tag you play with your doctor when results finally do arrive," Genalyte CEO Cary Gunn said in a statement.

In 2012, Genalyte raised $11.8 million in Series B financing. In 2013, the firm landed a $1 million Small Business Innovation Research grant from the National Cancer Institute to develop a biomarker panel for tumor antigen-associated antibodies.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.